{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T05:28:26Z","timestamp":1767331706264,"version":"3.48.0"},"reference-count":33,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T00:00:00Z","timestamp":1767312000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>This study aims to identify the risk factors for infection in patients with multiple myeloma (MM) and to develop a predictive model for infection.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We retrospectively analyzed the clinical data of 180 multiple myeloma patients with MM who underwent chemotherapy at the First Affiliated Hospital of Jishou University from January 2017 to December 2022. A predictive model for infection events was constructed based on these data.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In the modeling group, 34 out of 90 patients (37.78%) experienced infections, whereas in the validation group, 40 out of 90 patients (44.44%) had infections. Binary logistic regression analysis showed that the levels of C-reactive protein level, fasting blood glucose level, lactate dehydrogenase level, Eastern Cooperative Oncology Group (ECOG) score, and the percentage of bone marrow plasma cell percentage were independent risk factors for infection in patients with MM (P &amp;lt; 0.05). The infection prediction model developed using these variables demonstrated good accuracy, with an area under the ROC curve of 0.827 (95% CI: 73.66%\u201391.78%) in the modeling group and for the validation group being 0.760 (95% CI: 65.97%\u201385.93%) in the validation group.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This study confirms that C-reactive protein level, fasting blood glucose level, lactate dehydrogenase level, ECOG score, and the percentage of bone marrow plasma cell percentage are significant risk factors for infection in patients with MM.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical significance<\/jats:title>\n                    <jats:p>This infection prediction model offers substantial clinical value by enabling a shift from reactive management to proactive, preventive intervention for infections in this vulnerable population.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2025.1672927","type":"journal-article","created":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T05:24:51Z","timestamp":1767331491000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Construction and validation of a simple, scoreable model for predicting infection risk in patients with multiple myeloma: a retrospective single-center study"],"prefix":"10.3389","volume":"15","author":[{"given":"Sheng-ke","family":"Tu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sha-dong","family":"Min","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong-jie","family":"Fan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mimi","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan","family":"Tian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kui","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,2]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26590","article-title":"Multiple myeloma: 2022 update on diagnosis, risk stratification, and management","volume":"97","author":"Rajkumar","year":"2022","journal-title":"Am J Hematol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1038\/s41408-020-00359-2","article-title":"Multiple myeloma current treatment algorithms","volume":"10","author":"Rajkumar","year":"2020","journal-title":"Blood Cancer J"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpp.2018.12.001","article-title":"Multiple myeloma in paleopathology: A critical review","volume":"24","author":"Riccomi","year":"2019","journal-title":"Int J Paleopathol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0098-9","article-title":"Front-line therapies for elderly patients with transplant-ineligible multiple myeloma and high-risk cytogenetics in the era of novel agents","volume":"32","author":"Avet-Loiseau","year":"2018","journal-title":"Leukemia"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23932","article-title":"Causes of early death in multiple myeloma patients who are ineligible for high-dose therapy with hematopoietic stem cell support: A study based on the nationwide Danish Myeloma Database","volume":"90","author":"Holmstr\u00f6m","year":"2015","journal-title":"Am J Hematol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1186\/s12879-020-05412-w","article-title":"Assessment of infection in newly diagnosed multiple myeloma patients: risk factors and main characteristics","volume":"20","author":"Lin","year":"2020","journal-title":"BMC Infect Dis"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1054\/blre.1999.0111","article-title":"Immune regulation in multiple myeloma: the host-tumour conflict","volume":"13","author":"Cook","year":"1999","journal-title":"Blood Rev"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2005.03.2086","article-title":"Early mortality after diagnosis of multiple myeloma: analysis of patients entered onto the United kingdom Medical Research Council trials between 1980 and 2002\u2013Medical Research Council Adult Leukaemia Working Party","volume":"23","author":"Augustson","year":"2005","journal-title":"J Clin Oncol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.critrevonc.2018.09.008","article-title":"Continuous therapy in standard- and high-risk newly-diagnosed multiple myeloma: A pooled analysis of 2 phase III trials","volume":"132","author":"D'Agostino","year":"2018","journal-title":"Crit Rev Oncol Hematol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"giz153","DOI":"10.1093\/gigascience\/giz153","article-title":"Prognostic model for multiple myeloma progression integrating gene expression and clinical features","volume":"8","author":"Sun","year":"2019","journal-title":"Gigascience"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(14)70442-5","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"8","DOI":"10.6004\/jnccn.2022.0002","article-title":"NCCN guidelines\u00ae insights: multiple myeloma, Version 3.2022","volume":"20","author":"Callander","year":"2022","journal-title":"J Natl Compr Canc Netw"},{"key":"B13","doi-asserted-by":"publisher","first-page":"3","DOI":"10.3390\/medsci9010003","article-title":"Epidemiology, staging, and management of multiple myeloma","volume":"9","author":"Padala","year":"2021","journal-title":"Med Sci (Basel)"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminoncol.2016.11.004","article-title":"Multiple myeloma epidemiology and survival: A unique Malignancy","volume":"43","author":"Kazandjian","year":"2016","journal-title":"Semin Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.01513","article-title":"Prevalence and incidence of multiple myeloma in urban area in China: A national population-based analysis","volume":"9","author":"Wang","year":"2019","journal-title":"Front Oncol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s13045-019-0706-9","article-title":"Mortality of lymphoma and myeloma in China 2004-2017: an observational study","volume":"12","author":"Liu","year":"2019","journal-title":"J Hematol Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/s2352-3026(21)00283-0","article-title":"Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working Group","volume":"9","author":"Raje","year":"2022","journal-title":"Lancet Haematol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24857","article-title":"Causes of early death in multiple myeloma patients treated with high-dose therapy followed by autologous stem cell transplantation: A study based on the nationwide Danish Multiple Myeloma Registry","volume":"92","author":"Thidemann Andersen","year":"2017","journal-title":"Am J Hematol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3346\/jkms.2016.31.4.510","article-title":"Pretreatment lymphopenia, poor performance status, and early courses of therapy are risk factors for severe bacterial infection in patients with multiple myeloma during treatment with bortezomib-based regimens","volume":"31","author":"Hyun","year":"2016","journal-title":"J Korean Med Sci"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2014.107714","article-title":"Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patients","volume":"100","author":"Blimark","year":"2015","journal-title":"Haematologica"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2014.117176","article-title":"European Myeloma Network guidelines for the management of multiple myeloma-related complications","volume":"100","author":"Terpos","year":"2015","journal-title":"Haematologica"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.4274\/Tjh.2012.0192","article-title":"Quality of life and supportive care in multiple myeloma","volume":"30","author":"C\u00f6mert","year":"2013","journal-title":"Turk J Haematol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1038\/s41408-022-00652-2","article-title":"A simple score to predict early severe infections in patients with newly diagnosed multiple myeloma","volume":"12","author":"Encinas","year":"2022","journal-title":"Blood Cancer J"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0133-x","article-title":"A predictive model for risk of early grade\u2009\u2265\u20093 infection in patients with multiple myeloma not eligible for transplant: analysis of the FIRST trial","volume":"32","author":"Dumontet","year":"2018","journal-title":"Leukemia"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3904\/kjim.2016.054","article-title":"Myeloma prognostic index at diagnosis might be a prognostic marker in patients newly diagnosed with multiple myeloma","volume":"32","author":"Kim","year":"2017","journal-title":"Korean J Intern Med"},{"key":"B26","doi-asserted-by":"publisher","first-page":"eaan6282","DOI":"10.1126\/scisignal.aan6282","article-title":"C-reactive protein promotes bone destruction in human myeloma through the CD32-p38 MAPK-Twist axis\u2019","volume":"10","author":"Yang","year":"2017","journal-title":"Sci Signal"},{"key":"B27","doi-asserted-by":"publisher","first-page":"e2945","DOI":"10.7759\/cureus.2945","article-title":"C-reactive protein monitoring predicts neutropenic fever following autologous hematopoietic stem cell transplantation for multiple myeloma","volume":"10","author":"Kollu","year":"2018","journal-title":"Cureus"},{"key":"B28","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/dmrr.682","article-title":"Common infections in diabetes: pathogenesis, management and relationship to glycaemic control","volume":"23","author":"Peleg","year":"2007","journal-title":"Diabetes Metab Res Rev"},{"key":"B29","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s43556-024-00188-w","article-title":"Multiple myeloma: signaling pathways and targeted therapy","volume":"5","author":"Lu","year":"2024","journal-title":"Mol Biomed"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.973836","article-title":"Drug resistance in multiple myeloma: Soldiers and weapons in the bone marrow niche","author":"Solimando","year":"2022","journal-title":"Front Oncol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21020613","article-title":"Bone marrow stromal cells-induced drug resistance in multiple myeloma","volume":"21","author":"Ria","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-2839","article-title":"VLA4-targeted nanoparticles hijack cell adhesion-mediated drug resistance to target refractory myeloma cells and prolong survival","volume":"27","author":"Fontana","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.21203\/rs.3.rs-3055773\/v1","article-title":"scoreable model for predicting infection risk in patients with multiple myeloma","author":"Tu","year":"2023"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1672927\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T05:24:52Z","timestamp":1767331492000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1672927\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,2]]},"references-count":33,"alternative-id":["10.3389\/fonc.2025.1672927"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1672927","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,2]]},"article-number":"1672927"}}